RT Journal Article
SR Electronic
T1 Inferring Transmission Fitness Advantage of SARS-CoV-2 Variants of Concern in Wastewater Using Digital PCR
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.22.21262024
DO 10.1101/2021.08.22.21262024
A1 Caduff, Lea
A1 Dreifuss, David
A1 Schindler, Tobias
A1 Devaux, Alexander J.
A1 Ganesanandamoorthy, Pravin
A1 Kull, Anina
A1 Stachler, Elyse
A1 Fernandez-Cassi, Xavier
A1 Beerenwinkel, Niko
A1 Kohn, Tamar
A1 Ort, Christoph
A1 Julian, Timothy R.
YR 2021
UL http://medrxiv.org/content/early/2021/08/31/2021.08.22.21262024.abstract
AB Throughout the global COVID-19 pandemic, SARS-CoV-2 genetic variants of concern (VOCs) have repeatedly and independently arisen. VOCs are characterized by increased transmissibility, increased virulence, or reduced neutralization by antibodies obtained from prior infection or vaccination. Tracking the introduction and transmission of VOCs relies on sequencing, typically whole-genome sequencing of clinical samples. Wastewater surveillance is increasingly used to track the introduction and spread of SARS-CoV-2 variants through sequencing approaches. Here, we adapt and apply a rapid, high-throughput method for detection and quantification of the frequency of two deletions characteristic of the B.1.1.7, B.1.351, and P.1 VOCs in wastewater. We further develop a statistical approach to analyze temporal dynamics in drop-off RT-dPCR assay data to quantify transmission fitness advantage, providing data similar to that obtained from clinical samples. Digital PCR assays targeting signature mutations in wastewater offer near real-time monitoring of SARS-CoV-2 VOCs and potentially earlier detection and inference on transmission fitness advantage than clinical sequencing.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding provided through the Swiss National Science foundation (Special Call on Coronaviruses (31CA30 196538), Federal Office of Public Health, Eawag and EPFL discretionary funding. XFC was a fellow of the European Unions Horizon 2020 research and innovation programme under the Marie Skłodowska Curie Grant Agreement No. 754462.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not Applicable. Data on clinical samples was obtained from a publicly available database covSPECTRUM (https://cov-spectrum.ethz.ch) and so ethical review was not sought.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data obtained from wastewater samples are available by contacting the authors, and will be archived in a public database upon article publication following peer review. The data on clinical samples were accessed by the publicly available covSPECTRUM database (https://cov-spectrum.ethz.ch).